EDGAR Filing Documents for 0000950170-24-029249

Form 8-K - Current report:

SEC Accession No. 0000950170-24-029249

Filing Date

2024-03-11

Accepted

2024-03-11 16:11:50

Documents

Period of Report

2024-03-11

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Interactive Data

Document Format Files

Seq	Description	Document	Type	Size
1	8-K	lxeo-20240311.htm iXBRL	8-K	83434
2	EX-99.1	lxeo-ex99_1.htm	EX-99.1	163599
3	EX-99.2	lxeo-ex99_2.htm	EX-99.2	16430
4	GRAPHIC	img46940271_0.jpg	GRAPHIC	249092
5	GRAPHIC	img47863792_0.jpg	GRAPHIC	249664
	Complete submission text file	0000950170-24-029249.txt		1089501

Data Files

Seq	Description	Document	Type	Size
6	XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT	lxeo-20240311.xsd	EX-101.SCH	25988
17	EXTRACTED XBRL INSTANCE DOCUMENT	lxeo-20240311_htm.xml	XML	4931

Mailing Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010

Business Address 345 PARK AVENUE SOUTH FLOOR 6 NEW YORK NY 10010 (212) 547-9879

Lexeo Therapeutics, Inc. (Filer) CIK: 0001907108 (see all company filings)

IRS No.: 854012572 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41855 | Film No.: 24738112
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)